Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Aneta H. Baran"'
Autor:
Leonidas C. Platanias, C. David James, Feng Yue, Aneta H. Baran, Amy B. Heimberger, Elspeth M. Beauchamp, Lukas D. Streich, Christopher Gonzalez, Sang Ho, Candice Mazewski, Jamie N. Guillen Magaña, Ricardo E. Perez, Frank Eckerdt, Mariafausta Fischietti
Glioblastoma (GBM) is an aggressive and incurable brain tumor in nearly all instances, whose disease progression is driven in part by the glioma stem cell (GSC) subpopulation. Here, we explored the effects of Schlafen family member 11 (SLFN11) in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::272b2dd522cfb16e2f766a234ff10a96
https://doi.org/10.1158/2767-9764.c.6550988
https://doi.org/10.1158/2767-9764.c.6550988
Autor:
Leonidas C. Platanias, C. David James, Feng Yue, Aneta H. Baran, Amy B. Heimberger, Elspeth M. Beauchamp, Lukas D. Streich, Christopher Gonzalez, Sang Ho, Candice Mazewski, Jamie N. Guillen Magaña, Ricardo E. Perez, Frank Eckerdt, Mariafausta Fischietti
Supplementary Table S3 lists proteins that were found to bind SLFN11 before or after irradiation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a8cab3fbb6d36c863c3001ac099363
https://doi.org/10.1158/2767-9764.22545635.v1
https://doi.org/10.1158/2767-9764.22545635.v1
Autor:
Leonidas C. Platanias, C. David James, Feng Yue, Aneta H. Baran, Amy B. Heimberger, Elspeth M. Beauchamp, Lukas D. Streich, Christopher Gonzalez, Sang Ho, Candice Mazewski, Jamie N. Guillen Magaña, Ricardo E. Perez, Frank Eckerdt, Mariafausta Fischietti
Fig. S1: Expression of SLFN family members after SLFN11 knockout. Fig. S2: Reduced 3-D invasion after SLFN11 knockout. Fig. S3: Expression of stem/progenitor markers after SLFN11 add-back. Table S1: Key resources table.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a27220299841390494e24b7f91b2db
https://doi.org/10.1158/2767-9764.22545641
https://doi.org/10.1158/2767-9764.22545641
Autor:
Leonidas C. Platanias, C. David James, Feng Yue, Aneta H. Baran, Amy B. Heimberger, Elspeth M. Beauchamp, Lukas D. Streich, Christopher Gonzalez, Sang Ho, Candice Mazewski, Jamie N. Guillen Magaña, Ricardo E. Perez, Frank Eckerdt, Mariafausta Fischietti
Supplementary Table S2 lists putative SLFN11 binding partners detected after untreated and/or irradiated cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e9c31d7d53d46755c06269cbc138f6f
https://doi.org/10.1158/2767-9764.22545638.v1
https://doi.org/10.1158/2767-9764.22545638.v1
Autor:
Leonidas C. Platanias, C. David James, Feng Yue, Aneta H. Baran, Amy B. Heimberger, Elspeth M. Beauchamp, Lukas D. Streich, Christopher Gonzalez, Sang Ho, Candice Mazewski, Jamie N. Guillen Magaña, Ricardo E. Perez, Frank Eckerdt, Mariafausta Fischietti
Supplementary Table S4 lists proteins that were found to bind SLFN11 after irradiation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e199c8b5cbe33bc943aee0c9999ce9f
https://doi.org/10.1158/2767-9764.22545632.v1
https://doi.org/10.1158/2767-9764.22545632.v1
Autor:
Mariafausta Fischietti, Frank Eckerdt, Ricardo E. Perez, Jamie N. Guillen Magaña, Candice Mazewski, Sang Ho, Christopher Gonzalez, Lukas D. Streich, Elspeth M. Beauchamp, Amy B. Heimberger, Aneta H. Baran, Feng Yue, C. David James, Leonidas C. Platanias
Publikováno v:
Cancer Res Commun
Glioblastoma (GBM) is an aggressive and incurable brain tumor in nearly all instances, whose disease progression is driven in part by the glioma stem cell (GSC) subpopulation. Here, we explored the effects of Schlafen family member 11 (SLFN11) in the
Autor:
Dominik A Nahotko, Aneta H Baran, Mariafausta Fischietti, Elspeth M Beauchamp, Leonidas C Platanias
Publikováno v:
Blood Cancer Discovery. 4:A39-A39
Mammalian target of rapamycin (mTOR) is a strong driver of tumorigenesis in multiple types of tumors, however targeting mTOR for cancer therapy has yielded only limited success. This may be explained in part by signaling redundancy with other pathway